Novo Nordisk Stock Plummets After Ozempic-Maker’s Alzheimer’s Drug Trial Fails

Novo Nordisk's Ozempic pill has failed to demonstrate efficacy in slowing the progression of Alzheimer's disease in two clinical trials, leading to a significant decline in the company's stock value. This disappointing outcome was reported by Naomi Kresge on Bloomberg Television.

Shares of Novo Nordisk have significantly declined following the announcement that its Ozempic pill did not slow the progression of Alzheimer’s disease in two major studies. This news comes amid broader economic concerns, including a drop in German business morale as the country struggles to recover from two years of economic contraction.

Shares of Novo Nordisk, the maker of Ozempic, have plummeted following the announcement that its medication failed to slow the progression of Alzheimer's disease in two significant clinical trials. This disappointing outcome has raised concerns about the company's future prospects in the Alzheimer's treatment market.

The stock market opened higher on November 24, 2025, with the Nasdaq and S&P 500 indices showing positive movement. However, shares of Novo Nordisk plummeted after the company's Ozempic medication failed to demonstrate efficacy in slowing Alzheimer's disease progression in clinical trials.

Novo Nordisk's shares have significantly declined following the announcement that its Ozempic medication failed to slow the progression of Alzheimer's disease in two major clinical trials. This outcome represents a substantial setback for one of Europe's largest listed companies, which had high hopes for the drug's efficacy in treating this debilitating condition.

European stocks remained steady, recovering from losses primarily caused by a significant drop in Novo Nordisk A/S shares following the failure of its Ozempic pill in Alzheimer's trials. Investors are also closely monitoring potential peace negotiations between Ukraine and Russia, which could impact market dynamics.